Tag Archives: Merck & Co.

Merck & Co (MRK) 22Q3 Update

22Q3 sales rose 13.7% to $15.0 billion with double-digit gains in KEYTRUDA and GARDASIL/GARDASIL 9.  GAAP diluted EPS fell 29.0% to $1.28; but non-GAAP diluted EPS rose 5.6% to $1.85.  The company recorded an $887 million ($0.27 per share) asset … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co (MRK) 22Q3 Update

Merck & Co (MRK) 22Q2 Update

22Q2 sales increased 28% to $14.6 billion, with LAGEVRIO sales of $1.2 billion, a 26% increase in KEYTRUDA sales to $5.3 billion and a 36% increase in GARDASIL/GARDASIL 9 sales to $1.7 billion.  GAAP diluted EPS from continuing operations increased … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co (MRK) 22Q2 Update

Merck & Co. (MRK) Update

Establishing 2022 and 2023 Estimates, Maintaining Outperform Rating, Setting $85 Price Target Following the spin-off of Organon, Merck is focused on growing its pharmaceuticals business to offset the looming loss of exclusivity on its $5 billion Januvia/Janumet franchise and others … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co. (MRK) Update

Assessing the Impact of the Organon Spin-Off on Merck

Merck is progressing toward the spin-off of its subsidiary, Organon & Co., which is expected to be completed by the end of the June.  Organon will include Merck’s women’s health products, biosimilars and certain established brands, most of which have … Continue reading

Posted in Health Care, MRK, OGN | Tagged , , , | Comments Off on Assessing the Impact of the Organon Spin-Off on Merck